Athira Pharma, Inc. (ATHA)

Market Cap	25.37M
Revenue (ttm)	n/a
Net Income (ttm)	-109.22M
Shares Out	38.44M
EPS (ttm)	-2.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,716,314
Open	0.715
Previous Close	0.750
Day's Range	0.620 - 0.715
52-Week Range	0.412 - 4.298
Beta	2.83
Analysts	Buy
Price Target	11.25 (+1,604.8%)
Earnings Date	Nov 7, 2024

About ATHA

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease dementia and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 18, 2020
• Employees: 67
• Stock Exchange: NASDAQ
• Ticker Symbol: ATHA
• Website: https://www.athira.com

Analyst Forecast

According to 4 analysts, the average rating for ATHA stock is "Buy." The 12-month stock price forecast is $11.25, which is an increase of 1,604.80% from the latest price.

Price Target

$11.25

(1,604.80% upside)

Analyst Consensus: Buy